(Q)-Twist analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer

被引：0
|
作者：
Chung, H. C.
Bang, Y.
Van Cutsem, E.
Kang, Y.
Hamamoto, Y.
Moiseyenko, V.
Gotovkin, E.
Urspruch, A.
Ducournau, P.
机构：
[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[3] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium
[4] Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan
[6] Inst Oncol, Dept Biotherapy & BMT, St Petersburg, Russia
[7] Ivanovo Reg Oncol Dispensary, Ivanovo, Russia
[8] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4048
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [32] A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
    Y-K Kang
    S Y Rha
    P Tassone
    J Barriuso
    R Yu
    T Szado
    A Garg
    Y-J Bang
    British Journal of Cancer, 2014, 111 : 660 - 666
  • [33] Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer
    Bonettil, A.
    Santoro, A.
    Ducournau, R.
    Cirrincione, A.
    Giuliani, G.
    Bell, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 224 - 224
  • [34] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial
    Extra, J. M.
    Cognetti, F.
    Maraninch, D.
    Snyder, R.
    Mauriac, L.
    Tubiana-Hulin, M.
    Chan, S.
    Grimes, D.
    Anton, A.
    Marty, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 125 - 126
  • [35] A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
    Kang, Y-K
    Rha, S. Y.
    Tassone, P.
    Barriuso, J.
    Yu, R.
    Szado, T.
    Garg, A.
    Bang, Y-J
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 660 - 666
  • [36] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
    Kang, Y.
    Kang, W.
    Shin, D.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M.
    Suarez, T.
    Santamaria, J.
    ANNALS OF ONCOLOGY, 2006, 17 : 19 - 19
  • [37] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
  • [38] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Gasparini, Giampietro
    Gion, Massimo
    Mariani, Luigi
    Papaldo, Paola
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    Torino, Francesco
    Spada, Antonella
    Zancan, Matelda
    De Sio, Livia
    Caputo, Antonio
    Cognetti, Francesco
    Lambiase, Antonio
    Amadori, Dino
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (03) : 355 - 365
  • [39] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Giampietro Gasparini
    Massimo Gion
    Luigi Mariani
    Paola Papaldo
    Diana Crivellari
    Gianfranco Filippelli
    Alessandro Morabito
    Vittorio Silingardi
    Francesco Torino
    Antonella Spada
    Matelda Zancan
    Livia De Sio
    Antonio Caputo
    Francesco Cognetti
    Antonio Lambiase
    Dino Amadori
    Breast Cancer Research and Treatment, 2007, 101 : 355 - 365
  • [40] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
12345